Hyderabad-based pharmaceutical company Suven Life Sciences has received three product patents from the Indian Patent Office (IPO) for new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative disesaes. The patents are valid until 2022. The granted claims of the patents include selective 5-HT compounds discovered by Suven and being developed by it as therapeutic agents for the treatment of disorders like Alzheimer's, attention deficient hyperactivity, Huntington's, Parkinson's and schizophrenia, the company stated in a press release today.Suven has so far filed 25 product patents out of which 10 have been cleared by the IPO. These are the first product patents granted to the company during its four years of the drug discovery programme.
